Jeil Pharmaceutical Co Ltd (271980) — Capital Reinvestment Ratio

Latest as of December 2025: 4.20x

Jeil Pharmaceutical Co Ltd (271980) has a Capital Reinvestment Ratio of 4.20x as of December 2025, meaning it reinvests 4% of its operating cash flow (₩532.03 Million) in capital expenditures (₩2.23 Billion). Check tangible equity quality of Jeil Pharmaceutical Co Ltd to evaluate the tangible quality of the company's equity base.

Capital Reinvestment Ratio

4.20x
Capex / Operating Cash Flow

Operating Cash Flow

₩532.03 Million
KRW

Capital Expenditures

₩2.23 Billion
KRW

Data as of

Dec 2025
Most recent filing

Jeil Pharmaceutical Co Ltd Capital Reinvestment Ratio (2018–2024)

This chart tracks Jeil Pharmaceutical Co Ltd's Capital Reinvestment Ratio across 4 annual periods. For the full cash flow conversion analysis, see how efficiently does Jeil Pharmaceutical Co Ltd generate cash.

Annual Capital Reinvestment Ratio for Jeil Pharmaceutical Co Ltd (2018–2024)

Year-by-year Capital Reinvestment Ratio for Jeil Pharmaceutical Co Ltd from 2018 to 2024. See Jeil Pharmaceutical Co Ltd free cash flow efficiency to measure how efficiently the company converts operating cash flow to free cash.

Year Reinvestment Ratio Operating CF (KRW) Capital Expenditures YoY Change
2024 2.06x ₩3.21 Billion ₩6.61 Billion ▲ +635.6%
2021 0.28x ₩19.10 Billion ₩5.34 Billion ▲ +646.2%
2019 0.04x ₩28.96 Billion ₩1.09 Billion ▼ -92.2%
2018 0.48x ₩21.45 Billion ₩10.29 Billion
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow